KOSDAQBiotech & Pharma950160

Kolon TissueGene

₩11,140▲ 2.20%2026-11-18 close
Market Cap
₩946.6B
Turnover
₩3.5B
Volume
310K
Shares out.
85M
PER
—
PBR
—
EPS
-₩577
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

TG-C misses primary endpoint; approval plan being reset

After TG-C's U.S. Phase 3 trial failed to reach statistical significance on its co-primary endpoints, Kolon TissueGene is reworking its approval path, while reported operating losses continue even though net profit appeared in the second and third quarters of 2026.

  1. 1

    The U.S. Phase 3 trial (15302 study) topline announced on July 20, 2026 did not reach statistical significance on the co-primary endpoints, and the company described the outcome as a partial success.

  2. 2

    On a disclosed basis, operating losses have continued for four years from 2022 to 2025, and the net loss attributable to controlling shareholders widened to KRW 180.7 billion in 2025.

  3. 3

    Net profit attributable to controlling shareholders was reported in the second and third quarters of 2026, yet operating losses of KRW 6.4 billion and KRW 10.9 billion over the same period suggest non-operating items played a large role.

  4. 4

    At year-end 2025, total liabilities were KRW 334.6 billion against total equity of KRW 59.6 billion, a debt ratio of 561.6% that rose sharply from 52.4% in 2024.

  5. 5

    The next checkpoints are the 2026 annual report due by late March 2027, and whether the FDA biologics license application (BLA) is filed in the first quarter of 2027 under a revised strategy.

02

Business structure

Kolon TissueGene develops TG-C, a cell and gene therapy for knee osteoarthritis that was previously marketed in Korea as Invossa. TG-C combines normal chondrocytes with cells engineered to express TGF-β1 and is given as a single injection into the knee joint, with the aim of relieving pain and improving joint function.

The product received a Korean approval in 2017 under the name Invossa-K, but the approval was cancelled in 2019 after the second cell component was identified as kidney-derived rather than the cartilage cells described in the approval file. The U.S.

FDA clinical program was briefly suspended before resuming in 2021, and trading in the company's shares resumed in October 2022. The core of the business is two U.S. Phase 3 trials supporting a BLA, with 1,066 patients enrolled in total and enrollment completed in July 2024.

For manufacturing and quality (CMC) preparation for approval, the company signed a contract with Lonza in October 2024. Annual revenue ranged from KRW 3.79 billion to KRW 9.77 billion over 2022 to 2025, so clinical and approval spending drives reported losses.

Several candidates target disease-modifying osteoarthritis drugs (DMOAD), and a 2025 review listed TG-C among 13 structure-modifying compounds in development. The company describes TG-C as the world's first cell and gene therapy for osteoarthritis under development.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.6B-₩3.4B−208.4%
2025Q4₩800M-₩7.4B−950.1%
2026Q1₩1.3B-₩4.9B−381.5%
2026Q2₩700M-₩6.4B−869.2%
2026Q3₩1.5B-₩10.9B−711.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.8B-₩16.8B-₩11.5B−172.4%−11.9%20.1%
2023₩3.8B-₩21B-₩17.6B−553.3%−14.8%17.4%
2024₩5B-₩21.5B-₩33.1B−433.6%−25.0%52.4%
2025₩4.8B-₩20.9B-₩180.7B−432.7%−303.2%561.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, annual revenue fell from KRW 9.77 billion in 2022 to KRW 3.79 billion in 2023, a 61.2% decline, then recovered to KRW 4.96 billion in 2024, a 31.0% increase, before edging down to KRW 4.84 billion in 2025, a 2.5% decline. Among 2022 to 2025, 2022 was the largest year and 2023 the smallest.

Operating losses were KRW 16.8 billion in 2022, KRW 21 billion in 2023, KRW 21.5 billion in 2024 and KRW 20.9 billion in 2025, a four-year run of losses in which the loss widened in 2023 and 2024 and narrowed in 2025.

The operating margin was -172.4% in 2022, -553.3% in 2023, -433.6% in 2024 and -432.7% in 2025, showing how fixed research and operating costs weigh heavily on a small revenue base.

The net loss attributable to controlling shareholders widened from KRW 11.5 billion in 2022 to KRW 17.6 billion in 2023, KRW 33.1 billion in 2024 and KRW 180.7 billion in 2025.

The 2025 net loss is far larger than the KRW 20.9 billion operating loss, which suggests non-operating or financial costs had a large effect, a point to be confirmed from the notes to the annual report.

Quarterly, the operating loss rose from KRW 3.38 billion in the third quarter of 2025 to KRW 7.42 billion in the fourth quarter, narrowed to KRW 4.9 billion in the first quarter of 2026, then widened to KRW 6.4 billion in the second quarter and KRW 10.9 billion in the third quarter, making five consecutive quarters of losses from the third quarter of 2025 through the third quarter of 2026.

Net income attributable to controlling shareholders moved from a KRW 115.8 billion loss in the fourth quarter of 2025 and a KRW 90.9 billion loss in the first quarter of 2026 to a KRW 44.6 billion profit in the second quarter, turning positive, and a KRW 113.1 billion profit in the third quarter.

A KRW 113.1 billion profit alongside a KRW 10.9 billion operating loss points to a large share of non-operating items. The net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, totals KRW 4.9 billion.

05

Industry analysis

The osteoarthritis treatment market is shifting from drugs that only relieve pain toward disease-modifying therapies (DMOAD) that alter joint structure or slow progression.

Osteoarthritis is described as a common degenerative disease affecting hundreds of millions of people worldwide, which keeps expectations for demand high. Past anti-NGF pain therapies from large pharmaceutical companies, however, saw approvals refused or Phase 3 programs halted.

Higher-dose safety signals and structural joint damage were cited as reasons that efficacy did not translate into commercialization. Such cases show how difficult it is to prove efficacy and safety together in osteoarthritis.

As a cell and gene therapy, TG-C carries manufacturing and quality requirements that differ from conventional chemical drugs, which makes CMC readiness a variable in the approval timeline. The company cites TG-C's inclusion among 13 structure-modifying compounds in a 2025 review as evidence of pipeline competitiveness.

Still, many candidates pursue the same goal, so its relative position may shift with clinical outcomes. In the U.S.

Phase 3 trial, pain and function improvements were seen in the TG-C arm but the difference versus placebo was not statistically proven, and the strong placebo response is a variable the market is watching.

06

Outlook

The nearest official milestone is the follow-up to the U.S. Phase 3 (15302 study) topline announced on July 20, 2026.

The company is analyzing the cause of the strong placebo response and said it would rebuild its approval strategy while keeping open the possibility of additional trials, taking into account the second Phase 3 (12301 study) result that had been scheduled for October 2026.

The company has framed the first-endpoint outcome as a growing pain rather than a failure. A May 2026 report cited the company's plan to file a BLA with the FDA in the first quarter of 2027 if results were positive, but that plan is now subject to the strategy revision that followed the July readout.

At BIO US 2026, the company planned more than 30 business meetings with global partners to explore technology exports and partnerships, and whether any deal is signed should be checked through regulatory filings. Manufacturing readiness rests on the CMC contract with Lonza signed in October 2024.

On the financial side, operating cash flow was negative every year from 2022 to 2025 against a debt-heavy balance sheet, so how the company funds work through approval and commercialization is a key variable.

The next full-year disclosure is the 2026 annual report, which will also show the notes explaining the profit in the second and third quarters of 2026. Whether a BLA is filed in the first quarter of 2027 will be the clearest sign of how the revised strategy plays out.

07

Valuation

PER
—
PBR
—
ROE
-21.1%
EPS
-₩577
BPS
—
Dividend per share
—

At year-end 2025, total equity was KRW 59.6 billion, of which the portion attributable to controlling shareholders was also KRW 59.6 billion, against total liabilities of KRW 334.6 billion. Current market capitalization sits far above that equity base, which places the share price at a large premium to book net assets.

Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, the net loss attributable to controlling shareholders totals KRW 4.9 billion, so no earnings-based multiple is calculated.

Net profit attributable to controlling shareholders was reported in the second and third quarters of 2026, which could change earnings-based multiples in future reports, but that profit appears to reflect non-operating items while operating losses continued, so its durability should be checked in the notes and the annual report.

The debt ratio rose from 20.1% in 2022 to 52.4% in 2024 and 561.6% in 2025. Within this balance sheet, the share price appears to reflect expectations tied to TG-C's clinical and approval progress more than current earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Efficacy signals despite missed primary endpoint

Pain relief and improved joint function were seen in the TG-C arm, and the company points to efficacy that looked stronger than in the earlier Korean Phase 3 and U.S. Phase 2 studies. Some secondary measures, including the rate of knee replacement surgery, were read as showing disease-modifying potential. The company is keeping additional trials open on that basis.

Partnering and licensing efforts

The company planned more than 30 business meetings with global partners at BIO US 2026 and said it is seeking commercialization deals with large pharmaceutical companies.

It also highlighted that a U.S. approval would make it the first Korean company to complete an FDA clinical program independently and enter overseas markets. Deal terms and timing have not yet been confirmed through disclosures.

Net profit attributable to controlling shareholders turned positive in Q2 and Q3 2026

On a disclosed basis, net profit attributable to controlling shareholders turned positive at KRW 44.6 billion in the second quarter of 2026 and KRW 113.1 billion in the third quarter. The first-quarter operating loss of KRW 4.9 billion was narrower than the KRW 7.42 billion loss in the fourth quarter of 2025.

Because operating losses widened again in the second and third quarters, whether the profit came from operations or one-off items must be confirmed in the annual report notes.

09

Bear factors

Co-primary endpoints not statistically significant

The U.S. Phase 3 trial (15302 study) did not reach statistical significance on its co-primary endpoints and did not prove a difference from placebo. A strong placebo response is under analysis, and the approval strategy is being rebuilt. Following the news, the share price fell to the daily limit down right after the market opened on July 21.

Cumulative losses and balance sheet strain

Operating losses have continued for four years from 2022 to 2025, and the net loss attributable to controlling shareholders widened to KRW 180.7 billion in 2025. Operating cash flow was negative every year from 2022 to 2025.

At year-end 2025, total liabilities were KRW 334.6 billion against equity of KRW 59.6 billion, a debt ratio of 561.6%. Further funding may be needed through the clinical and approval stages.

Past Invossa history and failed rival programs

TG-C follows Invossa, whose Korean approval was cancelled in 2019, so restoring regulatory trust remains a challenge. The temporary hold on the U.S. trial earlier adds to regulatory burden.

In osteoarthritis, large companies' anti-NGF therapies saw approvals refused or trials halted, which underlines how hard market entry is.

10

Risk factors

Clinical and approval risk

Because the approval strategy is being reset after the missed primary endpoint, the BLA filing timeline could slip. If additional trials are required, both development time and costs would rise. The second Phase 3 result and discussions with the FDA will shape the final approval path.

Financing risk

At year-end 2025, total liabilities stood at 561.6% of equity, and operating cash flow was negative each year. With research spending continuing before approval, the funding method will have a large effect on shareholder value. Whether the profit driven by non-operating items persists also needs to be checked.

Manufacturing and regulatory trust risk

Cell and gene therapies face demanding manufacturing and quality verification requirements, and CMC data becomes central at the approval stage. The October 2024 contract with Lonza supports this work, but failure to meet production standards could delay the timeline. Regulators' scrutiny stemming from the Invossa episode also remains a burden.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report. Check full-year 2026 results, the cause of the profit turn in the second and third quarters (notes on non-operating items), and the revised approval strategy.

  2. First quarter 2027

    Whether the FDA biologics license application (BLA) is filed. The key question is whether the target the company stated in May 2026 holds after the strategy revision that followed the July readout.

  3. May 15, 2027

    Deadline for the first-quarter 2027 quarterly report. Check the operating loss trend, research cost structure, and whether non-operating gains continue after the profit turn.

12

Overall view

Kolon TissueGene's core asset, TG-C, did not reach statistical significance on the co-primary endpoints of its U.S. Phase 3 trial, and the company is now rebuilding its approval strategy.

Pain relief and function improvement signals, the second Phase 3 result and the possibility of further trials, and partnering efforts are the positive factors.

On the other side, operating losses have continued for four years from 2022 to 2025, the net loss attributable to controlling shareholders widened to KRW 180.7 billion in 2025, and the debt ratio at year-end 2025 was 561.6%.

The turn to net profit in the second and third quarters of 2026 came while operating losses continued, so its durability and cause need checking. The share price appears to reflect expectations around TG-C's clinical and approval progress more than current earnings, and market capitalization sits far above equity.

The next checkpoints are the 2026 annual report due by late March 2027 and whether a BLA is filed in the first quarter of 2027. This report is for information only and does not present an investment rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. d1io3yog0oux5.cloudfront.net
  2. comp.fnguide.com
  3. voicewith.com
  4. digitaltoday.co.kr
  5. g-enews.com
  6. m-i.kr
  7. meconomynews.com
  8. m.thinkpool.com
  9. m.news.nate.com
  10. discoverynews.kr
  11. fnnews.com
  12. kpanews.co.kr
  13. v.daum.net
  14. mt.co.kr
  15. v.daum.net
  16. v.daum.net
  17. thebionews.net
  18. biz.newdaily.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis